General form of registration statement for all companies including face-amount certificate companies

Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)

v3.20.2
Stockholders' Equity (Deficit) and Capitalization (Detail Textuals) - USD ($)
1 Months Ended 12 Months Ended
Dec. 20, 2019
Nov. 30, 2019
Feb. 16, 2018
Jan. 19, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2020
Nov. 15, 2018
Dec. 28, 2017
Equity [Line Items]                  
Common stock, shares authorized         500,000,000 500,000,000 500,000,000 500,000,000  
Common stock gross proceeds         $ 1,919,372 $ 3,095,908      
Warrant liability, issuance costs           137,192      
2018 Emerald Financing Warrants                  
Equity [Line Items]                  
Warrants exercise 40,800,000       40,800,000        
Intrinsic value of warrant exercises         $ 4,284,000        
Number of warrants issued         40,800,000        
Warrant exercise price         $ 0.10   $ 0.10    
Series B Warrants                  
Equity [Line Items]                  
Intrinsic value of warrant exercises           $ 144,375      
Number of warrants issued           187,500 312,500    
Warrant exercise price             $ 0.00   $ 0.10
Direct offering                  
Equity [Line Items]                  
Number of stock sold   8,000,000              
Common stock, par value (per share)   $ 0.001              
Net proceeds from the transaction   $ 1,919,372              
Number of warrants issued   8,000,000              
Private placement                  
Equity [Line Items]                  
Emerald financing issuance costs         $ 154,092        
Warrant liability, issuance costs         137,192        
Reduction to APIC from the issuance of common stock         $ 16,900        
Securities Purchase Agreement | Emerald Health Sciences Inc                  
Equity [Line Items]                  
Common stock issued     15,000,000 15,000,000          
Number of warrants issued     20,400,000 20,400,000          
Warrant exercise price     $ 0.10 $ 0.10          
Common stock gross proceeds       $ 1,500,000          
Subsequent financing purchase price, description       The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.          
Term of warrants     5 years            
Securities Purchase Agreement | Emerald Health Sciences Inc | Accredited Investor                  
Equity [Line Items]                  
Common stock issued     2,500,000            
Number of warrants issued     3,400,000            
Warrant exercise price     $ 0.10            
Common stock gross proceeds     $ 1,750,000            
Term of warrants     5 years